Senate Republicans are coming around to the $40,000 cap on state and local tax deduction key House lawmakers demand in President Trump’s massive tax package.
In addition to cutting most of its staff, including two C-suite executives, Leap Therapeutics is winding down research and development activities and considering a sale or partnership opportunities.
In May, Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new funding from Royalty Pharma, the biotech has withdrawn that runway end date.
The industry is awaiting SEC approval for dozens of applications, even as Vanguard’s shareholder case highlights some of the tax complexity of the looming shift.